Logo

BMS Reports Positive Results of Eliquis (apixaban) in P-IV AUGUSTUS Study for NVAF/ACS/PCI

Share this

BMS Reports Positive Results of Eliquis (apixaban) in P-IV AUGUSTUS Study for NVAF/ACS/PCI

Shots:

  •  The P-IV AUGUSTUS study involves assessing of Eliquis (apixaban) vs vitamin K antagonists (VKAs) & aspirin vs PBO in 4-614 patients with non-valvular atrial fibrillation (NVAF)- acute coronary syndrome (ACS) & undergoing percutaneous coronary intervention (PCI) with P2Y12 inhibitor with or without aspirin
  • The P-IV AUGUSTUS study results: low mortality rate (23.5% vs 27.4% & 26.2% vs 24.7%); ischemic events (6.7% vs 7.1% & 6.5% vs 7.3%); CRNM bleeding (10.5% vs 14.7% & 16.1% vs. 9.0%)
  • Eliquis (apixaban-5mg/2.5mg- q2d) is an oral anticoagulant targeting factor Xa inhibitor to prevent thromboembolic event and has received FDA’s approval on December 28- 2012 & August 21- 2014 for atrial fibrillation & recurring DVT and PE respectively

Click here to read full press release/ article

Ref: BMS | Image: BMS


Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions